PRMT5-mediated FUBP1 methylation accelerates prostate cancer progression

Strategies beyond hormone-related therapy need to be developed to improve prostate cancer mortality. Here, we show that FUBP1 and its methylation were essential for prostate cancer progression, and a competitive peptide interfering with FUBP1 methylation suppressed the development of prostate cancer. FUBP1 accelerated prostate cancer development in various preclinical models. PRMT5-mediated FUBP1 methylation, regulated by BRD4, was crucial for its oncogenic effect and correlated with earlier biochemical recurrence in our patient cohort. Suppressed prostate cancer progression was observed in various genetic mouse models expressing the FUBP1 mutant deficient in PRMT5-mediated methylation. A competitive peptide, which was delivered through nanocomplexes, disrupted the interaction of FUBP1 with PRMT5, blocked FUBP1 methylation, and inhibited prostate cancer development in various preclinical models. Overall, our findings suggest that targeting FUBP1 methylation provides a potential therapeutic strategy for prostate cancer management.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Investigation
Published
2024-08-15
DOI
https://doi.org/10.1172/jci175023
Citations
11
Primary Topic
Cancer-related gene regulation
Type
article
Field-Weighted Citation Impact
2.57

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

PRMT5-mediated FUBP1 methylation accelerates prostate cancer progression

Zengming Wang, Xuebin Zhang, Luonan Chen, Jun Qin et al.
11 citations
Journal of Clinical Investigation
Cancer-related gene regulation
2.57
article

PRMT5-mediated FUBP1 methylation accelerates prostate cancer progression

Zengming Wang, Xuebin Zhang, Luonan Chen, Jun Qin, Xiao Hu, Shengsong Huang, Lichen Yin, Weiwei Yan, Denglong Wu, Zhenfei Li, Yang Liu, Jiahui Chen, Kai Xiao, Ping Wu, Li-Ming Sun, Chao Peng, Xuefeng Qiu
article en
11 citations

Abstract

Strategies beyond hormone-related therapy need to be developed to improve prostate cancer mortality. Here, we show that FUBP1 and its methylation were essential for prostate cancer progression, and a competitive peptide interfering with FUBP1 methylation suppressed the development of prostate cancer. FUBP1 accelerated prostate cancer development in various preclinical models. PRMT5-mediated FUBP1 methylation, regulated by BRD4, was crucial for its oncogenic effect and correlated with earlier biochemical recurrence in our patient cohort. Suppressed prostate cancer progression was observed in various genetic mouse models expressing the FUBP1 mutant deficient in PRMT5-mediated methylation. A competitive peptide, which was delivered through nanocomplexes, disrupted the interaction of FUBP1 with PRMT5, blocked FUBP1 methylation, and inhibited prostate cancer development in various preclinical models. Overall, our findings suggest that targeting FUBP1 methylation provides a potential therapeutic strategy for prostate cancer management.

Journal of Clinical InvestigationVol. 134(18)
Tongji University (CN), Shanghai Jiao Tong University (CN), Chinese Academy of Sciences (CN), Soochow University (CN), Shanghai Institute of Nutrition and Health (CN), Nanjing Drum Tower Hospital (CN), Shanghai Advanced Research Institute (CN), Center for Excellence in Molecular Cell Science (CN), Tongji Hospital (CN), University of Chinese Academy of Sciences (CN), Nanjing University (CN)
Natural Science Foundation of Shanghai, National Natural Science Foundation of China, Chinese Academy of Sciences
Good health and well-being
Openalex Percentile: Top 10%
Cancer-related gene regulation
2.57
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.